HIGHLIGHTS
- who: Ruili Yin and colleagues from the Beijing Key Laboratory of Diabetes Prevention and Research, Center for Endocrine Metabolic and Immune Diseases have published the research: Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment, in the Journal: Molecules 2022, 27, 3055. of /2022/
- what: Considering that the activity of DPP4 is already completely inhibited when DPP4i is used at its therapeutic dose, any increase in exposure to the drug will not have a further hypoglycemic effect (since the enzyme cannot be inhibited by more than 100%).
- how: This review discusses the role . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.